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CD161 is a type II transmembrane glycoprotein with characteristics of the C-type lectin superfamily, which
has recently been shown to promote T cell expansion. In this study, the role of T cells expressing CD161 as a
predictor for the occurrence of acute graft-versus-host disease (aGVHD) after allogeneic stem cell trans-
plantation (SCT) was investigated. Sixty-one patients who underwent ﬁrst allogeneic SCT were enrolled. At
engraftment, the expression of CD3, CD4, CD8, CD161, CD16, and CD56 was analyzed by ﬂow cytometry. After
adjusting for potential variables by univariate analysis, we performed a multivariate analysis, which revealed
a low frequency of CD8þCD161þ cells (P ¼ .034) and a high ratio of CD4þCD161þ to CD8þCD161þ cells
(P ¼ .001) were associated with the occurrence of aGVHD with a grade of  II. Moreover, the frequency of
CD8þCD161þ T cells was negatively correlated with aGVHD grade. A separate analysis for visceral aGVHD
showed similar results, with a low frequency of CD8þCD161þ T cells (P ¼ .031) or a high ratio of CD4þCD161þ
to CD8þCD161þcells (P < .001), indicating a high risk. Also, the predictive role of serum IL-17 levels for the
occurrence of aGVHD was identiﬁed, and RORgT was more highly expressed in CD4þCD161þ T cells than in
CD8þCD161þ T cells after allogeneic SCT (P ¼ .032). Although our study was limited by the heterogeneity and
small number of patients, these results suggest that the CD8þ subset of CD161þ T cells may have regulatory
effects and that they provide a basis for predicting the occurrence of aGVHD after allogeneic SCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Acute graft-versus-host disease (aGVHD) is a majorbarrier to the successful application of allogeneic stem cell
transplantation (SCT). Donor T cells that recognize minor or
major histocompatibility differences in the host are critical
mediators of aGVHD [1]. Numerous trials have been
conducted in an effort to determine the role of T cell subsets
in clinical aGVHD by studying speciﬁc cytokines in the serum
of patients with aGVHD [2-4] and in lesional tissue biopsies
[5-7]. In addition, ongoing research is focused on the
development of biomarkers and other non-HLAedependent
factors, such as polymorphisms of cytokine genes and gene
expression proﬁles of CD4þ and CD8þ T cells from donors, as
predictors of aGVHD.edgments on page 427.
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ty for Blood and Marrow Transplantation.CD161 is a type II transmembrane glycoprotein with
characteristics of the C-type lectin superfamily and is
expressed on natural killer (NK) cells, 25% of adult peripheral
T cells, more than 90% of peripheral blood monocytes, and
in vitroederived dendritic cells [8]. Iliopoulou et al. [8] re-
ported that CD4þCD161þ T cells were signiﬁcantly increased
in cancer patients and that they may play an immunoregu-
latory role through cytokine production. Shimamoto et al. [9]
showed that the abundance of CD161þ (CD161þCD3þ) T cells
in colonic mucosal tissues in patients with ulcerative colitis
was inversely correlated with the severity of inﬂammation,
indicating this T cell population may contribute to intestinal
inﬂammation in ulcerative colitis. Mitsuo et al. [10] reported
that CD161þCD8þ T cells were decreased in the peripheral
blood of patients suffering from rheumatic diseases,
demonstrating that CD161þCD8þ T cells are a subpopulation
of CD8þ NK T (NKT) cells and exert regulatory effects on
immune tolerance.
CD161þ T cells are able to produce IL-17 and display an
activated Th17 phenotype, as indicated by increased
Table 1
Patients and Transplantation Characteristics
Parameters All Patients (n ¼ 61)
Median age, yr (range) 40 (18-71)
Sex of patient, M/F 33 (54)/28 (46)
Sex of donor, M/F 36 (59)/25 (41)
Sex pair
Female to male/others* 17 (28)/44 (72)
Hematopoietic cell transplantation
comorbidity index
<3/3 41 (67)/20 (33)
Diagnosis
AML/CML/MDS 28 (46)/2 (3)/14 (23)
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Although the role of Th17 cells in the development of aGVHD
has been evaluated, the results are still confusing and con-
tradictory [13,14]. Moreover, the role of CD161þ T cells in the
development of aGVHD has not been evaluated. From this
point of view, we conducted this prospective study to eval-
uate the association of each subset of CD161þ T cells with the
development of aGVHD. We found that each subset of
CD161þ T cells at engraftment potentially predicted the
occurrence of aGVHD by differentially expressing the Th17
transcription factor.ALL/MM 9 (15)/1 (2)
Aplastic anemia 7 (11)
Pre-SCT disease status
Standard/advanced 38 (62)/23 (38)
Donor type
Sibling/unrelated/FMT 32 (53)/25 (40)/4 (7)
Sources of graft
BM/PBSC 22 (36)/39 (64)
Conditioning regimen
TBI based/non-TBI based 31 (51)/30 (49)
Conditioning intensity
MAC/RIC 45 (74)/16 (26)
ATG containing
Yes/no 29 (48)/32 (53)
Median CD34þ cells dose,  106/kg (range) 4.7 (.6-21.5)
Median CD3þ cells dose,  107/kg (range) 35.5 (2.2-103.8)
GVHD prophylaxis
CS based/FK506 based 32 (53)/29 (48)
aGVHD (grade II)
Yes/no 25 (41)/36 (59)
Median days to aGVHD onset (range) 33 (9-83)
Grade at aGVHD onset
II/III-IV 15 (25)/10 (16)
Organ target at aGVHD onset
Skin only/visceral organ 7 (11)/18 (30)
Chronic GVHD
Mild/moderate/severe 6 (10)/15 (25)/4 (7)
Median days to chronic GVHD onset (range) 109 (36-284)
AML indicates acute myeloid leukemia; CML, chronic myelogenous leuke-METHODS
Patients and Transplant Procedures
This study examined 61 consecutive adult patients who underwent
allogeneic SCT from siblings or unrelated donors at our institute between
March 2010 and September 2010. The analysis of risk factors for aGVHD was
performed in all patients. This study was approved by the Institutional Re-
view Board and conducted in accordance with the Declaration of Helsinki.
Donor selection was based on molecular typing for HLA-A, HLA-B, HLA-
C, and DRB1. Patients received either a myeloablative conditioning regimen
(n ¼ 45), including total body irradiation (TBI)/cyclophosphamide, ﬂudar-
abine/busulfan, TBI/cytarabine/melphalan, or busulfan/cyclophosphamide,
or a reduced-intensity regimen (n ¼ 16), including ﬂudarabine and busulfan
with TBI 400 cGy or ﬂudarabine and melphalan. Overall, 22 patients
received bone marrow and 39 received granulocyte colony-stimulating
factor (G-CSF)-mobilized peripheral blood stem cells. Antithymocyte glob-
ulin (2.5 mg/kg; IMTIX-Sangstat, Lyon, France) was administered as part of
the conditioning regimen to reduce aGVHD in patients who received not
only transplants from mismatched unrelated donors but also peripheral
blood stem cells from matched unrelated donors.
aGVHD prophylaxis was attempted by administering a calcineurin in-
hibitor (cyclosporine for most related transplants and tacrolimus for all
unrelated transplants) along with short-term administration of metho-
trexate. The calcineurin inhibitor dose was tapered gradually starting on day
100 to day 120 after allogeneic SCT in the absence of aGVHD. G-CSF
(lenograstim, 5 mg/kg/day) was administered subcutaneously to all patients
from day þ7 after transplantation until the absolute neutrophil count was
>3.0  109/L. The other general transplantation procedures were performed
as described previously [15,16].mia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic anemia;
MM, multiple myeloma; FMT, HLA-mismatched familial donor; BM, bone
marrow; PBSC, peripheral blood stem cell; TBI, total body irradiation; MAC,
myeloablative conditioning; RIC, reduced-intensity conditioning; ATG,
antithymocyte globulin; CS, cyclosporine.
Values are number of cases with percents in parentheses, unless otherwise
noted.
* Other sex pairs (donorerecipient) included male to male (n ¼ 19), fe-
male to female (n ¼ 11), and male to female (n ¼ 14).Diagnosis and Management of aGVHD
aGVHD is deﬁned as the manifestation of GVHD rather than the time of
onset after allogeneic SCT [16,17]. In this study, patients with overlap syn-
dromewho developed both acute and chronic features simultaneously or de
novo aGVHD followed by chronic features with persistence of the former
acute features were included in the events of aGVHD at the onset of acute
features. Visceral aGVHD included liver and intestinal manifestation
regardless of skin involvement [18]. The primary treatment for aGVHD
mainly consisted of methylprednisolone (2 mg/kg) or an equivalent dose of
prednisone, and the treatments of steroid-refractory aGVHD were variable,
as described in a previous report [19].Blood Sample Collection and Isolation of Mononuclear Cells
Blood samples for the analyses of T cell populations were taken after the
day of neutrophil engraftment, which was deﬁned as the ﬁrst of 3 consec-
utive days with an absolute neutrophil count > .5  109/L. Brieﬂy, the
sampling was done after at least 3 days of discontinuation of G-CSF
administration. In addition, when the speciﬁc types of WBCs were not
normalized, the blood sampling was delayed until the differential cell count
was recovered within the normal range. Peripheral blood mononuclear cells
(PBMCs) were isolated fromwhole blood (10 mL) in an EDTA-coated tube by
centrifugation in Ficoll-Paque and were processed freshly.Flow Cytometric Analysis
Allophycocyanin-conjugated anti-CD3 mAb, FITC-conjugated anti-CD4
mAb, FITC-conjugated anti-CD8 mAb, and PerCP-Cy5.5-conjugated anti-
CD161 mAb were purchased from eBioscience (San Diego, CA). Flow
cytometry was performed using a FACSCalibur (BD Biosciences, San Diego,
CA). The proportions of CD4þCD161þ and CD8þCD161þ T populations gated
on CD3þ cells after allogeneic SCTwere evaluated, and the absolute numbers
of CD4þCD161þ and CD8þCD161þ T cells were calculated using the per-
centages of these cells in the mononuclear cell count.ELISA
Blood samples for the measurement of serum IL-17 were obtained from
an additional 59 patients at engraftment. Serum IL-17 levels were tested
using a commercially available ELISA (R&D Systems, Minneapolis, MN). Each
sample was tested in duplicate, and the average is reported in picogram per
milliliter. The sensitivity of detection ranged from 1 to 1000 pg/mL. Patient
and transplant characteristics are summarized in Supplemental Table 1.
Quantitative Reverse Transcriptase PCR
PBMCs of 10 patients who underwent allogeneic SCT were obtained on
the day of neutrophil engraftment. Quantitative reverse transcriptase (qRT)-
PCR for expression of RORgT was performed on CD4þCD161þ and
CD8þCD161þ T cell subsets. RORgT expression was determined using the
following primers (sense: 50-AGAAGGACAGGGAGCCAAG-30; antisense: 50-
CAAGGGATCACTTCAATTTGTG-30). PCR ampliﬁcation was performed using a
C1000 Touch Thermal Cycler (CFX96; Bio-Rad, Hercules, CA) under the
following conditions: 28 cycles of denaturation at 94C for 30 seconds,
annealing at 55C for 60 seconds, and elongation at 72C for 30 seconds.
Patient and transplant characteristics are summarized in Supplemental
Table 1.
Statistical Analysis
Statistical comparisons between groups were performed using a chi-
square or Fisher’s exact test for categorical variables or the nonparametric
Table 2
Characteristics of Cell Populations at Engraftment According To the Occurrence of aGVHD
Parameters Healthy Volunteers (n ¼ 4) No aGVHD (n ¼ 36) aGVHD (Grade  II) (n ¼ 25) aGVHD (Grade  III-IV) (n ¼ 10)
MNC,  106 cells/mL 1.3 (1.1-1.5) 1.1 (.2-4.3) 1.2 (.1-3.0) 1.4 (.9-2.4)
Frequency of cell population at engraftment, %
CD3þ 69.1 (65.3-80.4) 6.1 (.1-47.8) 12.1 (.1-71.8) 16.4 (.1-71.8)
CD4þCD161þ 14.9 (8.7-21.9) 9.0 (0-26.1) 10.7 (.7-33.2) 11.2 (.7-33.2)
CD8þCD161þ 12.9 (7.7-16.3) 9.8 (.8-71.4) 7.5 (0-22.2) 5.2 (0-21.2)
CD56þCD16þ 31.1 (27.7-43.5) 5.4 (.1-45.3) 2.8 (.1-33.6) 3.7 (.1-33.6)
Absolute count of cell population, cells/mL
CD3þ 926.0 (768.6-1141.1) 62.4 (.5-985.9) 110.0 (.1-1304.8) 187.2 (.1-926.7)
CD4þCD161þ 204.6 (123.3-241.3) 87.6 (0-501.4) 118.3 (4.3-342.1) 127.6 (36.8-273.6)
CD8þCD161þ 160.2 (118.4-202.4) 111.2 (5.6-777.5) 93.0 (0-425.6) 72.0 (0-290.5)
CD56þCD16þ 406.8 (342.9-617.8) 57.3 (1.4-507.4) 33.0 (.2-521.7) 35.6 (.2-402.0)
MNC indicates mononuclear cell.
Values are medians, with ranges in parentheses.
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was used to estimate the probability of aGVHD, treating nonrelapse death
and relapse as respective competing risks.
The analysis of risk factors for grades II to IV aGVHD was performed,
followed by a separate analysis for grades III to IV aGVHD, because grades III
to IV aGVHD had substantial effects on mortality risk. For the prediction of
aGVHD, the effects of T cell populations on the cumulative incidence of
aGVHD were assessed. To investigate whether the identiﬁed markers are
independent predictors, additional presenting and transplant covariates
having a P < .1 for association with aGVHD in the univariate analyses were
added to a Cox proportional hazards regression model.
SAS software was used (SAS Institute, Inc., Cary, NC), and information on
the required data format for these analyses can be found at http://
www.biomedcentral.com/content/supplementary/cc6852-S1.pdf. Cumula-
tive incidence functions of aGVHD were computed with R functions from
competing risk analysis libraries (R software, version 2.9.1; R foundation for
Statistical Computing, Vienna, Austria).Table 3
Univariate Analyses of Risk Factors for Cumulative Incidence of aGVHD
Univariate Variables aGVHD (Grade  II)
Hazard Ratio (95% CI) P
High age, yr (continuous) .98 (.95-1.01) .29
Sex pair*
Femaleemale 1
Others 2.29 (.77-6.78) .14
High frequency of CD8þCD161þ, %y .96 (.93-1.00) .05
High frequency of CD4þCD161þ, % 1.03 (.98-1.08) .21
High absolute count of CD8þCD161þ, cells/mL 1.01 (1.00-1.02) .25
High absolute count of CD4þCD161þ, cells/mL 1.01 (1.00-1.03) .07
High CD4þCD161þ/CD8þCD161þ ratio 1.03 (1.02-1.04) <.00
Donor type
Sibling 1
Others 1.38 (.64-2.98) .41
Sources of graft
BM 1
PBSC .83 (.38-1.81) .64
Pre-SCT disease status
Standard 1
Advanced .57 (.24-1.35) .20
Conditioning regimen
TBI based 1
Non-TBI based .86 (.40-1.86) .70
Conditioning intensity
MAC 1
RIC .87 (.35-2.14) .75
ATG given as conditioning
Yes 1
No 1.41 (.64-3.12) .39
GVHD prophylaxis
CS based 1
FK506 based 1.38 (.64-2.98) .41
CI indicates conﬁdence interval.
* Sex pair is expressed as donor to recipient.
y Increasing frequency and absolute count of CD8þCD161þ/CD4þCD161þ and
variables.RESULTS
Patients and Transplant Characteristics
Sixty-one patients were analyzed in this study (Table 1),
consisting of 33 men and 28 women with a median age of
40 years (range, 18 to 71). Patients with various hematologic
malignancies (n ¼ 54) and aplastic anemia (n ¼ 7) received
transplants from sibling donors (n ¼ 32), unrelated donors
(n ¼ 25), or HLA-mismatched familial donors (n ¼ 4). At the
time of the transplant, 23 patients (38%) had advanced dis-
ease features, which are deﬁned as acute leukemia beyond
the ﬁrst remission, chronic myelogenous leukemia beyond
the ﬁrst chronic phase, high-risk myelodysplastic syndrome
(international prognostic scoring system  intermediate-2),
and multiple myeloma with chemoresistance. The medianaGVHD (Grades III-IV) Visceral aGVHD
Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
0 .95 (.90-1.00) .045 .97 (.93-1.00) .064
1 1 .250
0 3.81 (.51-28.8) .190 2.07 (.59-7.21)
4 .91 (.83-1.00) .048 .93 (.87-1.00) .042
0 .99 (.92-1.06) .750 1.03 (.97-1.10) .310
0 .99 (.96-1.03) .750 .97 (.91-1.03) .350
1 1.00 (.96-1.03) .800 .98 (.95-1.02) .330
1 1.03 (1.02-1.08) <.001 1.04 (1.03-1.06) <.001
1 1
0 .75 (.21-2.60) .650 .54 (.20-1.46) .230
1 1
0 1.30 (.34-5.01) .700 .52 (.21-1.28) .150
1 1
0 1.75 (.52-5.89) .360 .59 (.21-1.63) .310
1 1
0 1.28 (.33-4.95) .720 .57 (.22-1.43) .230
1 1
0 1.02 (.30-3.45) .980 .80 (.26-2.45) .700
1 1
0 1.36 (.39-4.73) .630 1.99 (.76-5.24) .160
1 1
0 .75 (.21-2.60) .650 .54 (.20-1.46) .230
increasing CD4þCD161þ/CD8þCD161þ ratio are analyzed as continuous
Figure 1. CD161 expression on CD4þ or CD8þ T cells at engraftment. Fluorescent activated cell sorter plots show representative CD4þCD161þ, CD8þCD161þ T cell, and
NK cell fractions in 1 healthy volunteer (A), 1 SCT patient who developed aGVHD (B), and 1 SCT patient who did not have aGVHD (C).
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lymphocytes, CD34þ cells, and CD3þ cells were 7.7  108
cells/kg (range, .9 to 104.4), 5.4  108 cells/kg (range, .4 to
19.4), 4.3  108 cells/kg (range, .4 to 14.3), 4.2  106 cells/kg
(range, .5 to 21.5), and 28.6  107 cells/kg (range, 2.2 to 96.3),
respectively.
Transplant Outcomes
All patients achieved engraftment. The median time-to-
neutrophil engraftment after SCT was 12 days (range, 4 to
24) and that for platelet engraftment was 17 days (range, 6 to
60). The median peripheral blood T cell donor chimerism at
engraftment was 98.7% (range, 60.8% to 100%). After aFigure 2. The relationship between the frequency of CD8þCD161þ T cells at
engraftment and the grade of aGVHD. The frequency of CD8þCD161þ T cells at
engraftment was inversely correlated with the severity of aGVHD.median follow-up of 22.6 months (range, 21.7 to 23.6) for
surviving transplant recipients, the 2-year overall survival
and disease-free survival rates were 72.7%  5.8% and
68.9%  5.9%, respectively, and the cumulative incidences of
relapse and nonrelapse mortality were 14.1%  4.6% and
19.9%  5.4%, respectively. Twenty-ﬁve patients developed
grades II to IV aGVHD between 9 and 83 days after transplant
(median onset, 33 days). Speciﬁcally, skin-only aGVHD
(n¼ 7) occurred at a median of 29 days (range, 21 to 70) after
SCT and visceral aGVHD (n ¼ 18) at a median of 36 days
(range, 9 to 83) after SCT. Overall, the cumulative incidence of
aGVHD was 41.0%  6.4%, including 15 patients with grade II
and 10 with grades III to IV.Analysis of CD161þ T Cells at Engraftment
The median time-to-sampling of CD161þ T cell analysis
after SCT was 19 days (range, 12 to 35). The median mono-
nuclear cell count was 1.2 106 cells/mL (range, .1 to 4.3) and
those of CD3þ cells, CD4þCD161þ cells, CD8þCD161þ cells,
and CD56þCD16þ cells were 72.6 (range, .1 to 1304.8), 97.9
(range, 0 to 501.4), 109.2 (range, 0 to 777.5), and 45.1 (range,
.2 to 521.7) cells/mL, respectively (Table 2). The frequency and
number of CD3þ cells and NK cells was signiﬁcantly lower in
patients undergoing allogeneic SCT than in healthy volun-
teers (P < .001 and P < .001 in frequency, respectively, and
P< .001 and P¼ .001, respectively, in absolute count). Among
the allogeneic recipients, the frequency of CD8þCD161þ cells
was lower in patients with aGVHD than in patients without
aGVHD (P ¼ .046), whereas those of CD4þCD161þ cells and
CD56þCD16þ cells were not.Predictive Factors for the Occurrence of aGVHD
The results of univariate analysis for potential risk factors
affecting the cumulative incidence of aGVHD are listed in
Figure 3. Cumulative incidence of aGVHD according to frequency of CD8þCD161þ T cells at engraftment. To explore the predictive role of the frequency of
CD8þCD161þ T cells at engraftment, SCT patients were divided into 2 groups, low CD8þCD161þ (7.5%) and high CD8þCD161þ (>7.5%), by a ROC curve analysis. (A)
Cumulative incidence of overall aGVHD with grade  II according to frequency of CD8þCD161þ T cells at engraftment. (B) The frequency of CD8þCD161þ T cells at
engraftment has a signiﬁcant predictive role for the occurrence of visceral aGVHD.
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CD4þCD161þ/CD8þCD161þ ratio at engraftment were po-
tential factors in predicting the occurrence of aGVHD with
grade  II. In particular, these 2 factors were associated with
severe aGVHD (grades III to IV) and visceral aGVHD. Younger
patient agewas also associated with the occurrence of severe
aGVHD (grades III to IV) and visceral aGVHD. Figure 1 shows
ﬂuorescent activated cell sorter plots indicating representa-
tive patterns of CD161 expression on CD4þ or CD8þ T cells
from 1 healthy volunteer, 1 SCT patient who developed
aGVHD, and 1 SCT patient who did not develop aGVHD. The
frequency of CD8þCD161þ T cells at engraftment was
inversely correlated with the grade of overall aGVHD
(Figure 2).
As shown in Figure 3, when patients were divided into 2
groups, low CD8þCD161þ (7.5%) and high CD8þCD161þ
(>7.5%), by a receiver operating characteristic (ROC) curve
analysis, we observed a signiﬁcant protective role of the
frequency of CD8þCD161þ T cells at engraftment against the
occurrence of visceral aGVHD. The CD4þCD161þ/
CD8þCD161þ ratio at engraftment also played a signiﬁcant
predictive role against the occurrence of aGVHD with
grade  II and visceral aGVHD (Figure 4). Model 1 of our
multivariate analysis (Table 4), including younger patient ageFigure 4. Cumulative incidence of aGVHD according to the CD4þCD161þ/CD8þCD161þ
engraftment, SCT patients were divided into 2 groups, low CD4þCD161þ/CD8þCD161þ
analysis. (A) Cumulative incidence of overall aGVHD with grade  II according to
CD8þCD161þ ratio at engraftment has a signiﬁcant predictive role for the occurrenceand frequency of CD8þCD161þ T cells, revealed that a low
frequency of CD8þCD161þ T cells was signiﬁcantly associated
with a higher risk for aGVHD. A separate analysis for visceral
aGVHD produced a similar result, with higher risk for aGVHD
in the presence of a low frequency of CD8þCD161þ Tcells and
a tendency toward higher risk for visceral aGVHD in younger
patients. Model 2 of our multivariate analysis (Table 4),
including younger patient age and the CD4þCD161þ/
CD8þCD161þ ratio, revealed that a higher CD4þCD161þ/
CD8þCD161þ ratio was signiﬁcantly associated with a higher
risk for aGVHD.Association of Serum IL-17 Levels with the Occurrence of
aGVHD
Considering the results of previous studies showing that
CD161-expressing T cells had features in common with Th17
cells [12,20], we also explored the predictive role of serum IL-
17 levels for the occurrence of aGVHD in an additional 59
patients (Supplemental Table 1). The patients were divided
into 2 groups, low IL-17 (<10 pg/mL) and high IL-17 (10 pg/
mL), by a ROC curve analysis. The patients with high serum
IL-17 at engraftment showed a higher cumulative incidence
of aGVHD (Figure 5).ratio. To explore the predictive role of the CD4þCD161þ/CD8þCD161þ ratio at
ratio (1.3) and high CD4þCD161þ/CD8þCD161þ ratio (>1.3), by a ROC curve
the CD4þCD161þ/CD8þCD161þ ratio at engraftment. (B) The CD4þCD161þ/
of visceral aGVHD.
Table 4
Multivariate Analyses of Risk Factors for Cumulative Incidence of aGVHD
Multivariate Variables aGVHD (Grade  II) Visceral aGVHD
Hazard Ratio
(95% CI)
P Hazard Ratio
(95% CI)
P
Model 1
High age, yr
(continuous)
.98 (.94-1.03) .210 .96 (.92-1.00) .057
High frequency of
CD8þCD161þ, %
(continuous)
.96 (.93-.99) .034 .94 (.88-.99) .031
Model 2
High age, yr
(continuous)
.99 (.95-1.02) .450 .97 (.93-1.01) .160
High CD4þCD161þ/
CD8þCD161þ
ratio (continuous)
1.03 (1.01-1.04) .001 1.04 (1.02-1.06) <.001
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High Levels of RORgT
Because a high ratio of CD4þCD161þ to CD8þCD161þT
cells at engraftment was associated with the occurrence of
aGVHD, we speculated that these cells obtained from the
patients at engraftment after allogeneic SCT had a different
function from healthy volunteers. PBMCs were obtained
from both healthy control subjects (n ¼ 4) and transplant
patients (n ¼ 10). Considering the impact of serum IL-17
levels on the occurrence of aGVHD, RORgT expression was
investigated using qRT-PCR on mRNA of sorted CD4þCD161þ
T cells and CD8þCD161þ T cells. CD4þCD161þ T cells from
patients after allogeneic SCT showed a higher RORgT mRNA
expression compared with that of healthy control subjects
(P ¼ .032) (data were normalized to that of healthy control
subject). In contrast, RORgT mRNA expression levels in
CD8þCD161þ T cells did not differ between healthy control
subjects and transplant patients (Figure 6).
DISCUSSION
In this prospective study, CD161 expression on CD4þ or
CD8þ T cells from healthy volunteers and the patients who
underwent allogeneic SCT was examined by ﬂow cytometric
analysis. The frequency of the CD161-expressing CD8þ T cells
at engraftment correlated with the subsequent development
and the severity of aGVHD, and the ratio of CD161þCD4þ to
CD161þCD8þ T cells was a powerful factor predicting the
occurrence of aGVHD. Additively, the predictive role of serumFigure 5. Cumulative incidence of aGVHD according to serum IL-17 levels. Serum IL-
were divided into 2 groups, low IL-17 (<10 pg/mL) and high IL-17 (10 pg/mL), by a R
the occurrence of aGVHD with grade  II (A) and visceral aGVHD (B).IL-17 levels at engraftment for the occurrence of aGVHD was
observed. The Th17 transcription factor RORgT was highly
expressed in CD4þCD161þ T cells rather than CD8þCD161þ T
cells, suggesting that each subset of CD161-expressing T cells
may have a different role in the regulation of aGVHD.
Several studies have identiﬁed a common feature of
CD161-expressing subsets of Tcells, and CD161was shown to
be a phenotypicmarker of humanTh17 cells. Kleinschek et al.
[12] isolated CD161þCD4þ cells from Crohn’s disease patients
and found that these CD161þCD4þ cells are a resting Th17
pool. Cosmi et al. [20] also reported that CD161þCD4þ T cells
from umbilical cord blood as well as postnatal thymus are of
the early Th17 lineage. van der Waart et al. [21] showed that
CD161-expressing T cells from allograft recipients also were
dominant producers of IL-17 within T cell compartments.
Interestingly, our study shows that the frequency of
CD8þCD161þ cells at engraftment was inversely correlated
with subsequent aGVHD severity and the absolute number of
circulating T cells (rs ¼ .283, P ¼ .027), suggesting that
CD8þCD161þ T cells may have regulatory functions. Mitsuo
et al. [10] found that CD8þCD161þ T cells were signiﬁcantly
decreased in the peripheral blood of patients suffering from
rheumatic diseases. Moreover, Ho et al. [22] demonstrated
that, of the Va24-invariant CD1d-restricted NKT cells, a
subset of CD4 Va24i NKT cells that express CD8a have im-
mune regulatory properties that inﬂuence the proliferation
of activated T cells. Takahashi et al. [23] also showed that
most human Va24þCD8þNKT cells express CD161 and
recognize CD1d.
Taken together, the above ﬁndings indicate that
CD8þCD161þ T cells may be CD8þ NKT cells that have the
regulatory function of inhibiting the proliferation of antigen-
speciﬁc activated T cells in humans. In the present study, a
signiﬁcant difference in RORgT mRNA expression levels be-
tween transplant recipients and healthy control subjects was
observed in CD4þCD161þ T cells but not in CD8þCD161þ T
cells. However, CD8þ T cells expressing high levels of CD161
have been reported to exhibit pro-inﬂammatory character-
istics in multiple sclerosis [24] and may play a role in the
pathogenesis of chronic hepatitis and arthritis and poten-
tially in other infectious and inﬂammatory diseases. Further
studies that show direct evidence to distinguish this popu-
lation of regulatory CD8þCD161þ T cells from conventional
CD8þ T cells, NK cells, and NKT cells in the context of allo-
geneic SCT are needed.17 from an additional 59 patients was measured at engraftment. The patients
OC curve analysis. The serum IL-17 levels have a signiﬁcant predictive role for
Figure 6. RORgT mRNA expression of CD4þCD161þ and CD8þCD161þ T cells
after allogeneic SCT. PBMCs from healthy donors (n ¼ 4) and allogeneic SCT
patients (n ¼ 10) were sorted by a ﬂuorescent activated cell sorter into
CD4þCD161þ (left) and CD8þCD161þ (right) T cells, and RORgT mRNA
expression was assessed by qRT-PCR (data were normalized to that of healthy
control subject). The boxes indicate interquartile range with median, and
whiskers deﬁne minimum to maximum values.
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role of Th17 cells in the occurrence of aGVHD have shown
conﬂicting results. The results of clinical studies are also
confusing and contradictory. Dander et al. [25] found that
Th17 cells were increased in the peripheral blood of pa-
tients with aGVHD, suggesting a role for Th17 cells in the
pathophysiology of aGVHD. In contrast, Broady et al. [26],
investigating skin tissue obtained from patients with
aGVHD, found that ex vivoestimulated T cells isolated from
the skin of patients with aGVHD had no IL-17 or IL-22.
Although the reasons for these different results are not
clear, possible explanations include the different origins of
the obtained samples (peripheral blood, skin, or gut) and
the timing of the evaluation, which may be critical because
of the plasticity of the Th17 lineage. Furthermore, contra-
dictory results were obtained in animal studies [13,14]. In
the present study, the frequency of each CD161-expressing
subpopulation within T cells such as the ratio of
CD4þCD161þ to CD8þCD161þ cells was a potential predictor
for aGVHD, even though the absolute number of each
subpopulation did not affect the occurrence of aGVHD.
These observations suggest that each subpopulation may
have a different role in the development of aGVHD. Thus,
further studies to characterize the phenotypes and to
assess the immunologic functions of CD161-expressing T
cells from patients who have undergone allogeneic SCT are
needed.
This study has several potential drawbacks that need to
be addressed. First, we were unable to analyze the func-
tional characteristics of the CD8þCD161þ or CD4þCD161þ T
cells after allogeneic SCT. To ascertain the molecular mech-
anisms underlying this plasticity, differential expression of
transcription factors or epigenetic modiﬁcations within
effector cytokine gene promoter and enhancer regions
should be investigated. Second, it is possible that circulating
CD8þCD161þ or CD4þCD161þ Tcells are involved in the early
stages of aGVHD pathogenesis, but, at the onset of aGVHD,
they may exit the circulation, possibly trafﬁcking to
inﬂamed tissues such as the intestine or skin. Further
studies are required to determine whether an association
exists between altered proportions of circulating and/ortissue-localized T cell subsets and the onset of aGVHD.
Finally, our study was limited by a small number of patients
and heterogeneity of patient and transplant characteristics
with regard to disease status, conditioning regimen, GVHD
prophylaxis including antithymocyte globulin, and source of
hematopoietic cells. Therefore, the independency of CD161-
expressing T cells as a predictor for aGVHD should be
interpreted with caution.
In summary, we demonstrate an association between the
expression of CD161þ on T cell subsets and the development
of aGVHD, suggesting a role for the distribution of CD161-
expressing T cells as a biologic marker for early prediction
of aGVHD. Our ﬁndings also have signiﬁcant clinical impli-
cations because early prediction of aGVHD based on CD161
expression on T cell subpopulations may help identify a
group of patients requiring intensiﬁed prophylactic strate-
gies; these observations should be validated in a large pa-
tient population.ACKNOWLEDGMENTS
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